PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.90%
G&A reduction while AGEN shows 6.81% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-61.84%
Other expenses reduction while AGEN shows 0.00% growth. Joel Greenblatt would examine efficiency.
-45.56%
Operating expenses reduction while AGEN shows 4.41% growth. Joel Greenblatt would examine advantage.
-45.56%
Total costs reduction while AGEN shows 4.41% growth. Joel Greenblatt would examine advantage.
8.78%
Interest expense growth while AGEN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
45.56%
EBITDA growth exceeding 1.5x AGEN's 3.38%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
45.56%
Operating income growth exceeding 1.5x AGEN's 3.18%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.89%
Tax expense reduction while AGEN shows 222.81% growth. Joel Greenblatt would examine advantage.
30.89%
Net income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
30.77%
EPS growth while AGEN declines. John Neff would investigate advantages.
30.77%
Diluted EPS growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.